North America Small Molecule Drug Delivery Market Growth and Recent Trends by 2027

North America small molecule drug delivery market is expected to reach US$  26,458.48 million by 2027 from US$  12,791.35  million in 2019. The market is estimated to grow at CAGR of 9.8% from 2020 to 2027.

The small molecules drugs are able to enter cells easily because of its low molecular weight. These molecules are better than monoclonal antibodies and other large molecule drugs due to their size, easy convertibility to oral form and cost affectivity. The discovery of novel small molecule entities that are capable of specific interactions represents a significant challenge in the early stages of drug discovery. In the recent years, the small molecules have witnessed significant attention over biologics, as there is an increasing demand for these drugs.

US Small Molecule Drug Delivery Market Revenue and Forecast to 2027 (US$ Million)

Market Insights

Growing Numbers of Small Molecules Drug Approvals

Small molecules offer innovative treatments for the four significant indications that account for over half of pharma growth globally: oncology, diabetes, autoimmune, and respiratory diseases. The increasing applications of small molecule drugs for the treatment of chronic diseases are driving the demand and approvals of these drugs in the market. In 2018, the US Food and Drug Administration’s (FDA) and Center for Drug Evaluation and Research (CDER) approved a record-high 59 new molecular entities (NMEs), exceeding the previous record of 53 NME approvals in 1996 and the 46 NMEs passed in 2017. In 2018, the FDA approved 59 new drugs, 71% of which were small molecules. Small molecules also dominated new drug approvals in 2019, accounting for 79% of all new molecular entities (NME) approvals, representing 38 of the 48 NMEs approved by the FDA in 2019.

Small molecule protein kinase inhibitors are becoming increasingly important in cancer therapy. Another area is to use in combination with large molecules as antibody–drug conjugates (ADC), allowing more precise treatment of cancer. This has led to increasing product approvals of small molecule drugs that are the prime factors for the growth of the small molecule drug discovery market.

Therapeutic Type- Based Market Insights

Based on therapeutic type, the small molecule drug delivery market is further segmented into oncology, central nervous system, cardiovascular, respiratory, orthopedics, immunology, rare diseases, and other therapeutic areas. The oncology segment held the largest share of the market in 2019, however, rare diseases is anticipated to register the highest CAGR in the market during the forecast period.

North America Small Molecule Drug Delivery Market, by Therapeutic Type– 2019 and 2027

Process/Phase -Based Market Insights

Based on process/phase, the small molecule drug delivery market is segmented into target discovery, target validation, lead generation and refinement, and preclinical development. The lead generation and refinement segment held the largest share of the market in 2019. Moreover, target discovery is estimated to register the highest CAGR during the forecast period.

North America Small Molecule Drug Delivery Market: Strategic Insights

Product launches and approvals are commonly adopted strategies by companies to expand their footprint worldwide and meet the growing demand. The players operating in the small molecule drug delivery market adopt the expansion, collaboration, and product launch strategies to enlarge customer base across the world. These strategies allow the players to maintain their brand name globally. For instance, in June 2019, Pfizer Inc. and Array BioPharma Inc. announced that they have entered into a definitive merger agreement under which Pfizer will acquire Array, a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need.

By Therapeutic Area

• Oncology
• Central Nervous System
• Cardiovascular
• Respiratory
• Orthopedics
• Immunology
• Rare Diseases
• Other Therapeutic Areas

By Process/Phase

• Target Discovery
• Target Validation
• Lead Generation and Refinement
• Preclinical Development

By Country

• North America
  • US
  • Canada
  • Mexico

 Company Profiles

• Pfizer Inc.
• Bristol-Myers Squibb Company
• Johnson & Johnson Services, Inc.
• Gilead Sciences, Inc.

North America Small Molecule Drug Delivery Market Players Density: Understanding Its Impact on Business Dynamics

The North America Small Molecule Drug Delivery Market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.